Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 78877, held by Zydus Pharms USA Inc. Topiramate.
As of Nov 15, 2026, ANDA 78877 (Topiramate), held by Zydus Pharms USA Inc, was first approved by FDA on Oct 14, 2009, with 19 approved supplements and 0 published complete response letters.
Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets and topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 14, 2009 | Original application | Approved | None posted |
| Topiramate15MG · capsule;oral | Topiramate | Rx |
| Topiramate25MG · capsule;oral | Topiramate | Rx |
| Topiramate50MG · capsule;oral | Topiramate | Rx |
| Sep 8, 2023 | Supplement 25Labeling · Standard review | Approved | None posted |
| May 25, 2023 | Supplement 24Labeling · Standard review | Approved | None posted |
| May 25, 2023 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jan 7, 2022 | Supplement 21Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 3Labeling | Approved | None posted |
| Jun 24, 2011 | Supplement 2Labeling | Approved | None posted |
| Jun 24, 2011 | Supplement 1Labeling | Approved | None posted |
| Oct 14, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters